BAYRY News and Press, Bayer AG ADR From 01/18/24

2024-01-18 07:32:22 ET More on Bayer Bayer Isn't Dead Breaking Up Bayer? Probably Not! Bayer Q3 2023 Results - Earnings Call Presentation For further details see: Bayer backs off potential breakup despite investor pressure - Bloomberg

2024-01-18 07:00:29 ET More on Argenx SE, Bayer, etc. Regeneron Pharmaceuticals Inc. (REGN) 42nd Annual JPMorgan Healthcare Conference - (Transcript) Why I Expect Regeneron To Keep Delivering For Investors In 2024 (Upgrade) argenx: Back To Earth After 2 Clinical Tria...

2024-01-17 16:25:10 ET More on Bayer Bayer Isn't Dead Breaking Up Bayer? Probably Not! Bayer Q3 2023 Results - Earnings Call Presentation For further details see: Bayer to cut 'many' management jobs in deal with worker groups

2024-01-14 12:50:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. International markets ...

2024-01-14 12:00:24 ET More on CRISPR, GSK, etc. Pfizer Is Part Of The 2024 Healthcare Sector Rally Cohort Impact Of Gene Therapies And Casgevy On Crispr AG And The Industry CRISPR Therapeutics AG (CRSP) 42nd Annual J.P. Morgan Healthcare Conference (Transcript) ...

2024-01-14 03:40:00 ET Summary Shanghai Argo Biopharma entered two agreements with Novartis for a total value of $4.2 billion. San Diego’s Ambrx Biopharma will be acquired by Johnson & Johnson for $2 billion. GSK plans to acquire Aiolos Bio, a San Francisco-London s...

2024-01-12 11:03:11 ET Summary Recursion Pharmaceuticals stock price has risen by nearly 50% in the past month, currently trading at around $11 per share. The company raised over $500 million in its IPO, making it the sixth-largest biotech-focused IPO of the decade. Recursion'...

2024-01-11 20:25:00 ET Summary We are value investors. In constructing portfolios for our clients, we seek out companies that we believe are trading in the market at significant discounts to their underlying value. These businesses must offer significant profit potential and be run by...

2024-01-10 12:15:00 ET Summary We are value investors. In constructing portfolios for our clients, we seek out companies that we believe are trading in the market at significant discounts to their underlying value. These businesses must offer significant profit potential and be run by...

2024-01-08 14:06:31 ET Disclosing its preliminary financials for Q4 2023, Regeneron Pharmaceuticals ( NASDAQ: REGN ) announced Monday that it intends to recognize ~$1.34B as U.S. net product sales from its blockbuster eye disease therapy Eylea during the quarter. Meanwhile, its ...